Sponsors should take action to protect commercially confidential information
In brief
The new Clinical Trials Regulation (CTR) became applicable on 31 January 2022, following achievement of the full functionality by the new Clinical Trials Information System (CTIS), bringing more transparency into the area of clinical trials.
CTIS is a publicly accessible system that contains the data submitted in accordance with the CTR. The CTIS was set up to streamline the flow of information between the EU member states, the sponsors and the EU members states and to enable access of the EU citizens to information on medicinal products. It is operated by the European Medicines Agency.
In principle, the information in the CTIS is public. However, to protect the legitimate economic interest of sponsors, the CTR provides for a carve-out to protect sponsors’ commercially confidential information. Sponsors will be able to rely on this carve-out as discussed in more detail below. Sponsors are advised to review the draft Guidance document on how to approach the protection of personal data and commercially confidential information in documents uploaded and published in the CTIS that is currently under the public consultation and submit their comments by 8 September 2022.
Read the full alert here.
